1. �׶�ҽ�ƴ�ѧ����������ͯҽԺƤ����
2. �����ж�ͯҽԺƤ����

Ѫ�����������Ӥ��������������֢Ѫ�������������صIJ���֢�����»��ݡ�����������Σ�����������б�����������������ĵð���������֢Ѫ����ȡ�ýϺõ���Ч�������������Ѫ�����Ļ��ư�������Ѫ�ܡ�����Ѫ������������Ѫ����Ƥ�������Ӻͼ��Գ���άϸ���������ӱ��Լ��ٽ�ϸ�����������������Ϊһ�ַ�ѡ���Ե�β-������ϼ������ú���������Ѫѹ���Ķ���������Ѫ�ǡ�֧���ܾ��εȲ�����Ӧ����˷���ʱҪ���ܼ������������

Hemangiomas are the most common benign tumor in infancy. Despite of their self-limited course, severe hemangiomas can be accompanied by severe complications, which may cause disfigurement and functional impairment, and even lead to life-threatening airway compromise. It has been reported that propranolol has a satisfactory efficacy in the treatment of severe hemangiomas. The proposed treatment mechanisms of propranolol in hemangiomas includes induction of vasoconstriction and apoptosis as well as inhibition of the production of vascular growth factors such as endothelial vascular growth factor and basic fibroblast growth factors. As a non-selective beta-blocker, propranolol may cause hypotension, bradycardia, hypoglycemia and bronchospasm, so, vital signs should be monitored in patients treated with this drug.

1. Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: clinical characteristicspredicting complications and treatment. Pediatrics 2006; 118: 882–887. 2 O. Enjolras, G.M, Breviere, G. Roger, M, Tovi, B, et al. Vincristine treatment for function- and life-threatening infantile hemangioma. Arch. Pediatr. 11 (February 2) (2004) 99–107. 3 Vincristine as a treatment for a large haemangioma threatening vital functions. Fawcett SL, Grant I, Hall PN, et al. Br J Plast Surg 2004; 57: 168-71. 4 Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. Ezekowitz RA, Mulliken JB, Folkman J. N Engl J Med 1992;326: 1456-63. 5 Treatment with interferon-alpha 2b in children with life-threatening hemangiomas. Jiminez-Hernandez E, Duenas-Gonzalez MT, Quintero-Curiel JL, et al. Dermatol Surg 2008; 34: 640-7. 6 C. Leaute-Labreze, E. Dumas de la Roque, T. Hubiche, et al. Propranolol for severe hemangiomas of infancy, N. Engl. J. Med. 358 (June 24) (2008) 2649–2651. 7 Lisa Buckmiller, MD; Umesh Dyamenahalli, MD; Gresham T. Richter, MD. Propranolol for Airway Hemangiomas: Case Report of Novel Treatment. Laryngoscope 119: October 2009, 2051-2054. 8 Alberto Marsciani, MD, Roberta Pericoli, MD, Rita Alaggio, MD, et al. Massive Response of Severe Infantile Hepatic Hemangioma to Propanolol. Pediatr Blood Cancer 2010;54:176. 9 Franc?oise Denoyelle, Nicolas Leboulanger, Odile Enjolras, et al. Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma. International Journal of Pediatric Otorhinolaryngology 73 (2009) 1168–1172. 10 T Theletsane, A Redfern, O Raynham, et al. Life-threatening infantile haemangioma: a dramatic response to propranolol. European Academy of Dermatology and Venereology 2009, 23: 1465-1466. 11 ����ƽ����ѧ��������ף���. С������������ڷ�����Ӥ��Ѫ�����Ľ�����Ч�밲ȫ������.�л�ҽѧ��־ 2009 89 (44). 12 Leslie P. Lawley, M.D.,Elaine Siegfried, M.D.,and Jane L. Todd, M.D. Propranolol Treatment for Hemangioma of Infancy: Risks and Recommendations. Pediatric Dermatology 2009; 26: 5610–5614. 13 Waseem Mousa, Kirsten Kues, Ellen Haas, et al. Successful treatment of a large hemangioma with propranolol. JDDG; 2009 Band 7: 1-3. 14 Micromedex R Healthcare Series [Internet database]. Greenwood Village, CO: Thomson Healthcare. Updated periodically. Available at: http://www.thomsonhc.com/hcs/ librarian/ND_T/HCS/ND_PR/Main/CS/68E386/DUPLI CATIONSHIELDSYNC/C313DB/ND_PG/PRIH/ND_ BHCS/SBK/3/ND_P/Main/PFPUI/D5129Kk2E4eFtP/PF ActionId/hcs.common.RetrieveDocumentCommon/DocId/6300-v/ContentSetId/30#secN101A6 (accessed on 5 January 2009). 15 Hoffman BB. Adrenoceptor antagonist drugs. In:Katzung BG, ed. Basic and clinical pharmacology, 10th ed. New York:McGraw-Hill, 2007:147–158. 16 Gottschling S, Schneider G, Meyer S, et al. Two infants with life-threatening diffuse neonatal hemangiomatosis treated with cyclophosphamide. Pediatr Blood Cancer 2006; 46: 239-42. 17 Burns CM, Rutherford MA, Boardman JP, et al. Patterns of cerebral injury and neuodevelopmental outcomes after symptomatic neonatal hypoglycemia. Pediatrics 2008; 122: 65-74.